Orbus Therapeutics, Inc.

Patients with glioblastoma can expect to live a median eight months after diagnosis, but two anticipated launches in 2024 and a rich development pipeline could improve that bleak clinical outlook. “Th

Three venture capital funds announced during the last two weeks of October have $989m to invest in life science companies, which should help keep the biopharmaceutical VC financing boom going beyond 2

IN VITRO DIAGNOSTICS 23andMe Inc. 23andMe completes $150mm Series E financing 23andMe Inc. , which sells DNA testing kits directly to consumers who contribute their data to large-scale genetic

Exact Sciences’ colorectal cancer test meets targets Preliminary results from the DeeP-C trial of Exact Sciences Corp. ’s Cologuard colorectal cancer screening test show the test has a specif